13 completed, 9 recruiting, 4 unknown, 2 active not recruiting. 14 Phase 2, 13 Phase 1, 3 Not applicable.
Follow Recurrent Cancer: new trials by email Literature Review of Recurrent Cancer trials Research Report on Recurrent Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Symptom Trajectory Approaches to Research Health surveys - Advanced Cancer, Metastatic Disease | Not yet recruiting | University of Wisconsin, Madison | 228 | 2026-12-01 | 2026-09-04 | |
| Spatially Fractionated Radiation Treatment for Gynaecological Cancers Spatially fractionated radiation therapy - Cervical Cancer, Gynecologic Cancer | Not applicable | Recruiting | Tata Memorial Hospital | 20 | 2024-10-04 | 2026-02-20 |
| A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors RO7617991, Tocilizumab - Refractory Cancer, Recurrent Cancer | Phase 1 | Withdrawn | Genentech, Inc. | 2024-09-30 | 2024-09-03 | |
| Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer Paxalisib, Opdualag, Irinotecan (drug) - Childhood Cancer, Childhood Solid Tumor | Phase 1 / Phase 2 | Recruiting | Australian & New Zealand Children's Haematology/Oncology Group | 90 | 2024-07-10 | 2026-01-28 |
| Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors loco-regional hyperthermia - Recurrent Cancer, Prostate Cancer | Phase 2 | Not yet recruiting | Charite University, Berlin, Germany | 110 | 2024-05-10 | 2023-12-26 |
| Personalized Neoantigen Peptide Vaccines for Solid Tumors Personalized Neoantigen Peptide Vaccine - Solid Tumors, Advanced Cancer | Phase 1 / Phase 2 | Recruiting | Seqker Biosciences, Inc. | 10 | 2024-03-01 | 2026-07-24 |
| Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer Penicillamine - Head and Neck Cancer, Recurrent Cancer | Phase 2 | Unknown | Nanfang Hospital, Southern Medical University | 10 | 2023-11-15 | 2023-11-18 |
| Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy SNK02 - Pathologically Confirmed Cancer Refractory to Conventional Therapy, Refractory Cancer | Phase 1 | Completed | NKGen Biotech, Inc. | 6 | 2023-08-23 | 2024-11-20 |
| IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors IMA402, IMA402 and checkpoint inhibitor, IMA402 and chemotherapy - Refractory Cancer, Recurrent Cancer | Phase 1 / Phase 2 | Recruiting | Immatics Biotechnologies GmbH | 400 | 2023-08-09 | 2026-09-01 |
| PREventing Second Cancers With DOSTARlimab Dostarlimab - Recurrent Cancer, Primary Cancer | Phase 2 | Recruiting | Centre Leon Berard | 400 | 2023-07-26 | 2024-07-15 |
| Feasibility Study of Lidocaine Infusion During Bowel Cancer Surgery for Cancer Outcome Lidocaine hydrochloride 2% for injection, 0.9% sterile Sodium Chloride solution for injection - Colorectal Cancer, Quality of Life | Not applicable | Unknown | Imperial College London | 50 | 2023-02-02 | 2023-06-09 |
| Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma Tranilast - Nasopharyngeal Carcinoma, Recurrent Cancer | Phase 2 | Unknown | Jian Guan | 18 | 2022-07-20 | 2023-10-06 |
| IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor IMA401 (Phase Ia), Pembrolizumab (Phase Ia), IMA 401 (Phase Ib) - Refractory Cancer, Recurrent Cancer | Phase 1 | Active not recruiting | Immatics Biotechnologies GmbH | 95 | 2022-05-19 | 2026-04-30 |
| Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma Chemotherapy - Oncology, Endometrial Cancer | Completed | ARCAGY/ GINECO GROUP | 200 | 2022-05-09 | 2023-09-06 | |
| Safety and Efficacy of SBRT in the Reirradiation for Ultra-central Thoracic Malignant Tumors stereotacitic body radiation therapy - Stereotactic Body Radiation Therapy, Irradiation; Reaction | Recruiting | Peking University Third Hospital | 40 | 2022-05-01 | 2023-12-27 | |
| A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma CYH33 - Ovarian Cancer, Recurrent Cancer | Phase 2 | Active not recruiting | Haihe Biopharma Co., Ltd. | 93 | 2021-10-11 | 2026-01-30 |
| Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors CEA CAR-T cells - Colorectal Cancer, Esophageal Cancer | Phase 1 | Completed | Chongqing Precision Biotech Co., Ltd | 30 | 2021-09-10 | 2026-07-09 |
| Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions Mobile-based empathetic communication support program to promote ACP discussion - End of Life Care, Advanced Cancer | Not applicable | Completed | Yosuke Uchitomi | 264 | 2021-09-06 | 2025-03-30 |
| Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients XRD-0394, Palliative radiotherapy - Metastasis, Locally Advanced Solid Tumor | Phase 1 | Completed | XRad Therapeutics Inc | 12 | 2021-08-24 | 2024-01-11 |
| Nanoparticles and Hypofractionated Protontherapy for Reirradiation of Pantumor Relapse Radiation by protontherapy associated to nanoparticles injection - Recurrent Cancer, Previous Radiation | Phase 2 | Withdrawn | Centre Francois Baclesse | 2021-03-01 | 2025-09-17 |
Showing 20 of 32. Sign in to see all of them.
Recurrence (32) · Neoplasms (15) · Neoplasm Metastasis (9) · Pancreatic Neoplasms (3) · Carcinoma, Squamous Cell (2) · Colorectal Neoplasms (2) · Esophageal Neoplasms (2) · Head and Neck Neoplasms (2) · Ovarian Neoplasms (2) · Uterine Cervical Neoplasms (2) · Anus Neoplasms (1) · Bile Duct Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Pancreatic Ductal (1)
Disease Attributes (32) · Pathologic Processes (32) · Pathological Conditions, Signs and Symptoms (32) · Neoplasms by Site (17) · Neoplasms (14) · Neoplastic Processes (9) · Neoplasms by Histologic Type (7) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Urogenital Diseases (6) · Urogenital Neoplasms (6) · Carcinoma (5) · Endocrine Gland Neoplasms (5)
Drug Therapy (3) · Nivolumab (3) · pembrolizumab (3) · Antibodies, Monoclonal (1) · CYH33 (1) · Health Surveys (1) · IRX 2 (1) · Injections (1) · Irinotecan (1) · Lidocaine (1) · Liver Transplantation (1) · Opdualag (1) · Pancreaticoduodenectomy (1) · Penicillamine (1) · Pharmaceutical Preparations (1)
Immatics US, Inc. (3) · Immatics Biotechnologies GmbH (2) · NKGen Biotech, Inc. (2) · ARCAGY/ GINECO GROUP (1) · Australian & New Zealand Children's Haematology/Oncology Group (1) · Centre Francois Baclesse (1) · Centre Leon Berard (1) · Chang Gung Memorial Hospital (1) · Charite University, Berlin, Germany (1) · Chongqing Precision Biotech Co., Ltd (1) · Dana-Farber Cancer Institute (1) · European Hepatocellular Cancer Liver Transplant Group (1) · Genentech, Inc. (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Haihe Biopharma Co., Ltd. (1)
United States (9) · China (5) · Germany (5) · France (3) · Australia (2) · Canada (2) · Italy (2) · Japan (2) · United Kingdom (2) · Austria (1) · India (1) · Mexico (1) · Netherlands (1) · Pakistan (1) · Spain (1)
Cedrik Britten, M.D. (2) · Cedrik Britten, MD (1) · Daniel Morgenstern, Dr (1) · David Ziegler, Prof (1) · Guan Jian, Ph.D. (1) · Jennifer Knox, M.D. (1) · Jian Guan, M.D (1) · Jingwang Bi, M.D (1) · Junjie Wang, M.D. (1) · Kristine Kwekkeboom, PhD, RN, FAAN (1) · Lakshmi Nayak, MD (1)
PMID 33867478, PMID 35287469, PMID 36977536, PMID 37387798, PMID 38701690, PMID 39886516, PMID 40205198, PMID 42219399
2016 (1), 2023 (1), R01CA307143 (1)